{"id":5674,"date":"2024-01-05T13:00:13","date_gmt":"2024-01-05T18:00:13","guid":{"rendered":"https:\/\/neoaptamers.com\/?p=5674"},"modified":"2026-04-13T13:14:09","modified_gmt":"2026-04-13T17:14:09","slug":"revolutionizing-disease-detection-the-aptamarker-platform","status":"publish","type":"post","link":"https:\/\/neoaptamers.com\/fr\/revolutionizing-disease-detection-the-aptamarker-platform\/","title":{"rendered":"Revolutionizing Disease Detection: The Aptamarker Platform"},"content":{"rendered":"<ul>\n<li><strong>Changement de paradigme des Aptamarkers :<\/strong> La plateforme Aptamarker de NeoVentures Biotechnology remet en question l'approche traditionnelle de la d\u00e9couverte de biomarqueurs en \u00e9liminant le besoin de comprendre d'abord la cause d'une maladie.<\/li>\n<li><strong>R\u00e9volutionner les soins de sant\u00e9 :<\/strong> Aptamarker permet l'identification de biomarqueurs de maladies sans les contraintes de comprendre la cause de la maladie, ce qui permet des diagnostics plus rapides et plus efficaces.<\/li>\n<li><strong>Implications Diverses :<\/strong> Le processus simplifi\u00e9 de d\u00e9couverte de biomarqueurs n'optimise pas seulement l'utilisation des ressources, mais \u00e9largit \u00e9galement l'application de la plateforme \u00e0 divers domaines m\u00e9dicaux, des maladies infectieuses au cancer, ouvrant ainsi une nouvelle \u00e8re de soins de sant\u00e9 cibl\u00e9s et personnalis\u00e9s.<\/li>\n<\/ul>\n<p>Dans le paysage en constante \u00e9volution de la biotechnologie, l'approche traditionnelle pour identifier les biomarqueurs et d\u00e9velopper des th\u00e9rapies et des diagnostics associ\u00e9s \u00e9tait bas\u00e9e sur la compr\u00e9hension de la cause d'une maladie. Ce processus implique de d\u00e9finir l'\u00e9tat de la maladie, d'identifier ses origines, puis de rep\u00e9rer les biomarqueurs li\u00e9s \u00e0 la condition. Cependant, NeoVentures Biotechnology r\u00e9\u00e9crit cette histoire avec sa plateforme r\u00e9volutionnaire Aptamarker, une technologie r\u00e9volutionnaire qui permet d'identifier les biomarqueurs de la maladie sans avoir besoin de comprendre d'abord la cause de la maladie.<\/p>\n<h2>Le Paradigme Traditionnel<\/h2>\n<p>De mani\u00e8re conventionnelle, le chemin vers la d\u00e9couverte de biomarqueurs a \u00e9t\u00e9 un parcours m\u00e9ticuleux qui commence par la caract\u00e9risation de la maladie et la compr\u00e9hension des m\u00e9canismes sous-jacents complexes. Les chercheurs rechercheraient ensuite des signatures mol\u00e9culaires ou des biomarqueurs associ\u00e9s \u00e0 l'\u00e9tat de la maladie, offrant des informations cruciales sur le diagnostic, le pronostic et les interventions th\u00e9rapeutiques potentielles. Cette approche a sans aucun doute contribu\u00e9 de mani\u00e8re significative aux progr\u00e8s m\u00e9dicaux, mais elle n\u00e9cessite souvent beaucoup de temps, de ressources et une compr\u00e9hension approfondie des voies biologiques complexes qui sous-tendent la maladie.<\/p>\n<h2>Entrez NeoVentures Biotechnologie<\/h2>\n<p>NeoVentures Biotechnology s'est impos\u00e9 comme un pionnier dans le domaine en introduisant une approche r\u00e9volutionnaire de la d\u00e9couverte de biomarqueurs. La plateforme Aptamarker utilise la m\u00e9thode de s\u00e9lection brevet\u00e9e Neomer, repr\u00e9sentant la prochaine g\u00e9n\u00e9ration de s\u00e9lection d'aptam\u00e8res et rempla\u00e7ant la m\u00e9thode SELEX traditionnelle. Cette m\u00e9thode r\u00e9volutionnaire transforme la s\u00e9lection d'aptam\u00e8res, autrefois consid\u00e9r\u00e9e comme un art peu reproductible, en un processus scientifique syst\u00e9matique et clos, garantissant la fiabilit\u00e9 et la coh\u00e9rence dans l'identification des biomarqueurs.<\/p>\n<h2>Comment fonctionnent les Aptamarkers<\/h2>\n<p>Aptamarker exploite la puissance des aptam\u00e8res, des mol\u00e9cules d'ADN monocat\u00e9naire qui se lient sp\u00e9cifiquement \u00e0 des mol\u00e9cules cibles. La m\u00e9thode de s\u00e9lection Neomer permet aux chercheurs d'identifier des biomarqueurs en comparant des \u00e9chantillons de personnes atteintes d'une maladie sp\u00e9cifique \u00e0 ceux de sujets en bonne sant\u00e9. En utilisant la s\u00e9lection d'aptam\u00e8res, Aptamarker peut identifier des biomarqueurs pr\u00e9sents (ou absents) dans les \u00e9tats pathologiques, contournant ainsi la n\u00e9cessit\u00e9 de d\u00e9chiffrer les facteurs causatifs de la maladie.<\/p>\n<h2>Impact sur les Th\u00e9rapies et les Diagnostics<\/h2>\n<p>Les implications de la plateforme Aptamarker de NeoVentures Biotechnology sont r\u00e9volutionnaires. Cette approche innovante rationalise le processus de d\u00e9couverte des biomarqueurs, permettant l'identification rapide de marqueurs de maladies potentiels. La capacit\u00e9 \u00e0 identifier des biomarqueurs sans comprendre enti\u00e8rement la cause de la maladie ouvre de nouvelles perspectives pour le diagnostic pr\u00e9coce, la m\u00e9decine personnalis\u00e9e et le d\u00e9veloppement de th\u00e9rapies cibl\u00e9es.<\/p>\n<ol>\n<li><strong>Diagnostic pr\u00e9coce :<\/strong> La capacit\u00e9 d'Aptamarker \u00e0 identifier pr\u00e9cocement les biomarqueurs peut ouvrir la voie au diagnostic pr\u00e9coce, permettant aux professionnels de la sant\u00e9 d'intervenir de mani\u00e8re proactive et potentiellement d'am\u00e9liorer les r\u00e9sultats pour les patients.<\/li>\n<li><strong>La m\u00e9decine de pr\u00e9cision :<\/strong> Le potentiel de la plateforme \u00e0 identifier des biomarqueurs sp\u00e9cifiques associ\u00e9s \u00e0 diff\u00e9rents \u00e9tats pathologiques permet le d\u00e9veloppement d'interventions th\u00e9rapeutiques personnalis\u00e9es et cibl\u00e9es. Ce passage d'une approche universelle \u00e0 la m\u00e9decine de pr\u00e9cision promet des traitements plus efficaces et adapt\u00e9s.<\/li>\n<li><strong>L'acc\u00e9l\u00e9ration du d\u00e9veloppement de m\u00e9dicaments:<\/strong> Avec un processus d'identification des biomarqueurs plus rapide et fiable, les d\u00e9lais de d\u00e9veloppement des m\u00e9dicaments peuvent \u00eatre consid\u00e9rablement r\u00e9duits. Cette acc\u00e9l\u00e9ration pourrait conduire \u00e0 des essais cliniques plus efficaces et, en fin de compte, \u00e0 un acc\u00e8s plus rapide \u00e0 des traitements innovants pour les patients.<\/li>\n<li><strong>L'optimisation des ressources :<\/strong> La m\u00e9thode rationalis\u00e9e d'Aptamarker r\u00e9duit au minimum les ressources n\u00e9cessaires \u00e0 la d\u00e9couverte des biomarqueurs. Cela pourrait potentiellement r\u00e9duire les co\u00fbts de recherche, rendant ainsi plus r\u00e9alisable l'exploration d'une gamme plus large de maladies et de conditions.<\/li>\n<li><strong>Application plus large :<\/strong> La polyvalence de la plateforme Aptamarker permet son application dans divers domaines de la maladie. Des maladies infectieuses au cancer et au-del\u00e0, l'innovation de NeoVentures Biotechnology a le potentiel d'avoir un impact sur un large \u00e9ventail de disciplines m\u00e9dicales.<\/li>\n<\/ol>","protected":false},"excerpt":{"rendered":"<p>Aptamarker Paradigm Shift: NeoVentures Biotechnology&#8217;s Aptamarker platform challenges the traditional approach to biomarker discovery by eliminating the need to first understand the cause of a disease. Revolutionizing Healthcare: Aptamarker enables the identification of disease biomarkers without the constraints of unraveling disease causation, leading to faster and more efficient diagnostics. Wide-ranging Implications: The streamlined biomarker discovery&hellip;&nbsp;<a href=\"https:\/\/neoaptamers.com\/fr\/revolutionizing-disease-detection-the-aptamarker-platform\/\" rel=\"bookmark\">Lire la suite &raquo;<span class=\"screen-reader-text\">Revolutionizing Disease Detection: The Aptamarker Platform<\/span><\/a><\/p>","protected":false},"author":2,"featured_media":5675,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":70,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[43],"tags":[],"class_list":["post-5674","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aptamarkers"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Revolutionizing Disease Detection: The Aptamarker Platform<\/title>\n<meta name=\"description\" content=\"Revolutionizing biomarker discovery, NeoVentures&#039; Aptamarker platform enables efficient diagnostics without understanding disease causation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neoaptamers.com\/fr\/revolutionizing-disease-detection-the-aptamarker-platform\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revolutionizing Disease Detection: The Aptamarker Platform\" \/>\n<meta property=\"og:description\" content=\"Revolutionizing biomarker discovery, NeoVentures&#039; Aptamarker platform enables efficient diagnostics without understanding disease causation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neoaptamers.com\/fr\/revolutionizing-disease-detection-the-aptamarker-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"neoaptamers\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-05T18:00:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-13T17:14:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/01\/Screenshot-2024-01-05-at-12.57.04\u202fPM.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1388\" \/>\n\t<meta property=\"og:image:height\" content=\"946\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Gregory Penner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gregory Penner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/revolutionizing-disease-detection-the-aptamarker-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/revolutionizing-disease-detection-the-aptamarker-platform\\\/\"},\"author\":{\"name\":\"Gregory Penner\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/641d6a3e016e13414b8d0d0ffd5847ad\"},\"headline\":\"Revolutionizing Disease Detection: The Aptamarker Platform\",\"datePublished\":\"2024-01-05T18:00:13+00:00\",\"dateModified\":\"2026-04-13T17:14:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/revolutionizing-disease-detection-the-aptamarker-platform\\\/\"},\"wordCount\":636,\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/revolutionizing-disease-detection-the-aptamarker-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Screenshot-2024-01-05-at-12.57.04\u202fPM.png\",\"articleSection\":[\"Aptamarkers\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/revolutionizing-disease-detection-the-aptamarker-platform\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/revolutionizing-disease-detection-the-aptamarker-platform\\\/\",\"name\":\"Revolutionizing Disease Detection: The Aptamarker Platform\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/revolutionizing-disease-detection-the-aptamarker-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/revolutionizing-disease-detection-the-aptamarker-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Screenshot-2024-01-05-at-12.57.04\u202fPM.png\",\"datePublished\":\"2024-01-05T18:00:13+00:00\",\"dateModified\":\"2026-04-13T17:14:09+00:00\",\"description\":\"Revolutionizing biomarker discovery, NeoVentures' Aptamarker platform enables efficient diagnostics without understanding disease causation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/revolutionizing-disease-detection-the-aptamarker-platform\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neoaptamers.com\\\/revolutionizing-disease-detection-the-aptamarker-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/revolutionizing-disease-detection-the-aptamarker-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Screenshot-2024-01-05-at-12.57.04\u202fPM.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Screenshot-2024-01-05-at-12.57.04\u202fPM.png\",\"width\":1388,\"height\":946,\"caption\":\"Disease Detection\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/revolutionizing-disease-detection-the-aptamarker-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neoaptamers.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revolutionizing Disease Detection: The Aptamarker Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"name\":\"Neoaptamers.com\",\"description\":\"Neoventures Biotechnology Inc.\",\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/neoaptamers.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\",\"name\":\"NeoVentures Biotechnology Inc.\",\"alternateName\":\"NVB\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"width\":500,\"height\":500,\"caption\":\"NeoVentures Biotechnology Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/neoventures-biotechnology-inc-\\\/\",\"https:\\\/\\\/www.reddit.com\\\/user\\\/NeoVenturesBiotech\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@neoaptamers7964\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/641d6a3e016e13414b8d0d0ffd5847ad\",\"name\":\"Gregory Penner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"caption\":\"Gregory Penner\"},\"description\":\"Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. \u00a0He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team.\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revolutionizing Disease Detection: The Aptamarker Platform","description":"Revolutionizing biomarker discovery, NeoVentures' Aptamarker platform enables efficient diagnostics without understanding disease causation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neoaptamers.com\/fr\/revolutionizing-disease-detection-the-aptamarker-platform\/","og_locale":"fr_FR","og_type":"article","og_title":"Revolutionizing Disease Detection: The Aptamarker Platform","og_description":"Revolutionizing biomarker discovery, NeoVentures' Aptamarker platform enables efficient diagnostics without understanding disease causation.","og_url":"https:\/\/neoaptamers.com\/fr\/revolutionizing-disease-detection-the-aptamarker-platform\/","og_site_name":"neoaptamers","article_published_time":"2024-01-05T18:00:13+00:00","article_modified_time":"2026-04-13T17:14:09+00:00","og_image":[{"width":1388,"height":946,"url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/01\/Screenshot-2024-01-05-at-12.57.04\u202fPM.png","type":"image\/png"}],"author":"Gregory Penner","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Gregory Penner","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/neoaptamers.com\/revolutionizing-disease-detection-the-aptamarker-platform\/#article","isPartOf":{"@id":"https:\/\/neoaptamers.com\/revolutionizing-disease-detection-the-aptamarker-platform\/"},"author":{"name":"Gregory Penner","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/641d6a3e016e13414b8d0d0ffd5847ad"},"headline":"Revolutionizing Disease Detection: The Aptamarker Platform","datePublished":"2024-01-05T18:00:13+00:00","dateModified":"2026-04-13T17:14:09+00:00","mainEntityOfPage":{"@id":"https:\/\/neoaptamers.com\/revolutionizing-disease-detection-the-aptamarker-platform\/"},"wordCount":636,"publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"image":{"@id":"https:\/\/neoaptamers.com\/revolutionizing-disease-detection-the-aptamarker-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/01\/Screenshot-2024-01-05-at-12.57.04\u202fPM.png","articleSection":["Aptamarkers"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/neoaptamers.com\/revolutionizing-disease-detection-the-aptamarker-platform\/","url":"https:\/\/neoaptamers.com\/revolutionizing-disease-detection-the-aptamarker-platform\/","name":"Revolutionizing Disease Detection: The Aptamarker Platform","isPartOf":{"@id":"https:\/\/neoaptamers.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/neoaptamers.com\/revolutionizing-disease-detection-the-aptamarker-platform\/#primaryimage"},"image":{"@id":"https:\/\/neoaptamers.com\/revolutionizing-disease-detection-the-aptamarker-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/01\/Screenshot-2024-01-05-at-12.57.04\u202fPM.png","datePublished":"2024-01-05T18:00:13+00:00","dateModified":"2026-04-13T17:14:09+00:00","description":"Revolutionizing biomarker discovery, NeoVentures' Aptamarker platform enables efficient diagnostics without understanding disease causation.","breadcrumb":{"@id":"https:\/\/neoaptamers.com\/revolutionizing-disease-detection-the-aptamarker-platform\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neoaptamers.com\/revolutionizing-disease-detection-the-aptamarker-platform\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/neoaptamers.com\/revolutionizing-disease-detection-the-aptamarker-platform\/#primaryimage","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/01\/Screenshot-2024-01-05-at-12.57.04\u202fPM.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/01\/Screenshot-2024-01-05-at-12.57.04\u202fPM.png","width":1388,"height":946,"caption":"Disease Detection"},{"@type":"BreadcrumbList","@id":"https:\/\/neoaptamers.com\/revolutionizing-disease-detection-the-aptamarker-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neoaptamers.com\/"},{"@type":"ListItem","position":2,"name":"Revolutionizing Disease Detection: The Aptamarker Platform"}]},{"@type":"WebSite","@id":"https:\/\/neoaptamers.com\/#website","url":"https:\/\/neoaptamers.com\/","name":"Neoaptamers.com","description":"Neoventures Biotechnology Inc.","publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/neoaptamers.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/neoaptamers.com\/#organization","name":"NeoVentures Biotechnology Inc.","alternateName":"NVB","url":"https:\/\/neoaptamers.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","width":500,"height":500,"caption":"NeoVentures Biotechnology Inc."},"image":{"@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/neoventures-biotechnology-inc-\/","https:\/\/www.reddit.com\/user\/NeoVenturesBiotech\/","https:\/\/www.youtube.com\/@neoaptamers7964"]},{"@type":"Person","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/641d6a3e016e13414b8d0d0ffd5847ad","name":"Gregory Penner","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","caption":"Gregory Penner"},"description":"Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. \u00a0He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team."}]}},"_links":{"self":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts\/5674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/comments?post=5674"}],"version-history":[{"count":5,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts\/5674\/revisions"}],"predecessor-version":[{"id":6495,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts\/5674\/revisions\/6495"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/media\/5675"}],"wp:attachment":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/media?parent=5674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/categories?post=5674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/tags?post=5674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}